Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (URGN)
NASDAQ:URGN
URGN Stock Chart & Stats
$23.58
-$0.02(-0.18%)
At close: 4:00 PM EST
$23.58
-$0.02(-0.18%)
Day’s Range― - ―
52-Week Range$3.42 - $30.00
Previous CloseN/A
Volume157.75K
Average Volume (3M)1.04M
Market Cap
$1.07B
Enterprise Value$960.30M
Total Cash (Recent Filing)$127.03M
Total Debt (Recent Filing)$129.94M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Mar 12, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding46,808,890
10 Day Avg. Volume1,010,242
30 Day Avg. Volume1,043,723
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)-51.87
Price to Sales (P/S)5.05
P/FCF Ratio-4.70
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue13.28
Enterprise Value/Gross Profit14.95
Enterprise Value/Ebitda-10.54
Forecast
1Y Price Target
$40.25Price Target Upside70.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Impact And Regulatory ProgressInitial UTOPIA pivotal data confirm UGN-103 clinical impact in-line with ZUSDURI, with the FDA agreeing to the regulatory plan to submit a New Drug Application.
Market DemandUroGen management indicated strong market demand for ZUSDURI, as evidenced by roughly $4.5M in preliminary demand revenue estimated during the month of October 2025 alone.
Revenue GrowthStrong initial demand should translate to Q4 inflection with more to follow the permanent J code, leading to more rapid and robust revenue recording.
Bears Say
Urogen Pharma News
URGN FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was $3.42 and its highest was $30.00 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $1.07B.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Mar 12, 2026 which is in 78 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Nov 06, 2025. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.692 by $0.002.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is -0.48.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 46,808,890 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.692. Following the earnings report the stock price went up 21.906%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in URGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Urogen Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.25 (70.70% Upside)
$40.25 (70.70% Upside)
Blogger Sentiment
Bullish
URGN Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 500.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
112.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-38.71%
Trailing 12-Months
Company Description
Urogen Pharma
Urogen Pharma Inc. is a biopharmaceutical company focused on developing innovative therapies for urological diseases, particularly bladder cancer. The company operates in the oncology sector and is dedicated to addressing unmet medical needs through its proprietary drug delivery technologies and product candidates. Urogen's core products include its lead drug candidate, UGN-101, which is designed for the treatment of high-grade urothelial carcinoma, as well as other therapies aimed at improving the standard of care for patients with complex urological conditions.
URGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a balanced view with strong progress in the ZUSDURI launch and JELMYTO revenue growth, offset by challenges in operational execution and increased expenses. The permanent J-code for ZUSDURI is anticipated to drive future growth, but current operational delays and increased net loss are notable concerns.View all URGN earnings summariesURGN Stock 12 Month Forecast
Average Price Target
$40.25
▲(70.70% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Phathom Pharmaceuticals
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
1.99% Insiders
3.30% Mutual Funds
49.90% Other Institutional Investors
38.07% Public Companies and
Individual Investors